Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HPV Vaccine

Conditions

HPV Vaccine, HPV Infection, HIV-1-infection

Trial Timeline

Sep 1, 2015 → Jan 1, 2019

NCT ID

NCT04711265

About Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine

Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine is a pre-clinical stage product being developed by Merck for HPV Vaccine. The current trial status is completed. This product is registered under clinical trial identifier NCT04711265. Target conditions include HPV Vaccine, HPV Infection, HIV-1-infection.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04711265	Pre-clinical	Completed	Sep 1, 2015	Jan 1, 2019	HPV Vaccine

Competing Products

20 competing products in HPV Vaccine

See all competitors

Product	Company	Stage	Hype Score
AZD1222	AstraZeneca	Pre-clinical	23
Vaxelis™	Merck	Approved	85
21-valent pneumococcal conjugate vaccine	Merck	Approved	85
Pneumococcal Vaccine	Merck	Approved	85
quadrivalent human papillomavirus vaccine + quadrivalent human papillomavirus vaccine	Merck	Pre-clinical	23
Tetanus & Diphtheria booster vaccine (Td) + TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine] + Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)	Merck	Pre-clinical	23
9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses + 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses + 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose	Merck	Phase 3	77
Gardasil-9	Merck	Approved	85
Rotarix + RotaTeq	Merck	Phase 3	77
Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinant	Merck	Approved	85
Seasonal Influenza Vaccine	Novartis	Phase 3	77
Fluad + Saline	Novartis	Approved	85
Monovalent inactivated influenza vaccine	Novartis	Phase 2	52
cTIV	Novartis	Phase 3	77
Monovalent inactivated influenza vaccine	Novartis	Phase 3	77
Fluad H5N1 Pandemic Influenza Vaccine	Novartis	Phase 2	52
13-valent pneumococcal conjugate vaccine + 7-valent pneumococcal conjugate vaccine	Pfizer	Phase 3	76
13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccine	Pfizer	Phase 3	76
13vPnC + 23vPS	Pfizer	Phase 3	76
13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccine	Pfizer	Approved	84

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved